hrs-5041 + abiraterone acetate + prednisone acetate

**hrs-5041 + abiraterone acetate + prednisone acetate** is an experimental pharmaceutical drug combination being investigated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). HRS-5041 is a **Proteolysis Targeting Chimera (PROTAC)** specifically designed to degrade the androgen receptor, thereby blocking androgen receptor signaling, which is a key driver in prostate cancer cell growth[4][6][7]. **Abiraterone acetate** is a prodrug of abiraterone, a selective and irreversible inhibitor of CYP17A1, an enzyme required for androgen biosynthesis; it thereby reduces androgen production, further suppressing prostate cancer progression[2][8]. **Prednisone acetate** is a synthetic corticosteroid used in these regimens to provide glucocorticoid replacement and mitigate the mineralocorticoid side effects caused by abiraterone-induced CYP17A1 blockade[2][8], while potentially offering modest therapeutic benefit and symptom management[2][8]. The combination aims to maximize androgen blockade through targeted receptor degradation, synthesis pathway inhibition, and hormonal support, representing a multi-modal approach to advanced prostate cancer not sufficiently addressed by single agents.